Causes of eosinophilic ascites - a systematic review

LARISA PINTE¹, CRISTIAN BAICUȘ¹,²

1- Internal Medicine Department, Colentina Clinical Hospital, Bucharest, Romania
2- Carol Davila School of Medicine, Bucharest, Romania

Running head: Eosinophilic ascites: a systemic review
ABSTRACT:

Background: In the last years an uprising interest for a relatively unknown entity, eosinophilic ascites (EA), has been recorded. Our aim is to investigate the potential causes of EA development, as well as clinical, laboratory, endoscopic and radiologic features, management and outcome in these patients.

Methods: The following research was performed on PubMed (MEDLINE) database using the medical subject headings [Mesh] terms "Ascites" AND "Eosinophils".

Results: A total of 284 results, dating from 1962 onwards, were found and abstracts were examined. 131 papers were excluded and the remaining 153 publications, consisting in case reports and series of cases, were analyzed. From 171 patients with EA, 127 subjects (74%) had EGE, 17 (10%) parasitic and fungal infections, 11 (7%) Hypereosinophilic syndrome and 16 patients (9%) less common diseases (eosinophilic pancreatitis, chronic eosinophilic leukemia, myelofibrosis, T-cell lymphoma, Churg Strauss Syndrome, Systemic lupus erythematosus, Familial paroxysmal polyserositis and Ménétrier's disease). High eosinophil blood count and IgE levels as well as gastrointestinal symptoms are frequent. The diagnosis is based on ascitic fluid analysis, imaging and endoscopic biopsies. Therapy with corticosteroids results in resolution of eosinophilic ascites in almost all patients.

Conclusion: In most cases, in the absence of allergy, parasitic infections, malignancy, hematological disorders, peritoneal tuberculosis, inflammatory bowel disease or autoimmune disease, EA develops as a manifestation of eosinophilic gastroenteritis.

Keywords: Ascites, Hypereosinophilia, Eosinophilic ascites, Eosinophilic gastroenteritis, Hypereosinophilic syndrome, parasitic infection, systematic review.

INTRODUCTION

Ascites often appears as a manifestation of various diseases such as cirrhosis, heart failure, neoplasia, tuberculosis or pancreatic disease. Depending on its development mechanism, peritoneal fluid might have various colors (translucent yellow, milk-colored, turbid, bloody, brown) with a SAAG below or above 1.1 g/ dl and various white blood cell count. The most common causes of ascites are parenchymal liver disease (78%) and malignancy (12%), followed by cardiovascular disease (5%).[1] Eosinophilic ascites (EA) is a rare disorder of unknown etiology, characterized by high eosinophil counts in the peritoneal fluid, reported in both adult and pediatric patients. We aimed to investigate the potential mechanisms of EA development.

MATERIAL AND METHODS

The following research was performed on PubMed (MEDLINE) database using the medical subject headings [Mesh] terms "Ascites" AND "Eosinophils".
A total of 284 results, dating from 1962 onwards, were found and abstracts were examined. Seventy-six papers without evidence of eosinophilic ascites, twenty-nine narrative reviews and later on twenty-six studies in whom the inclusion criteria was not EA (13 regarding patients with EGE, 10 parasitic infections and another 3 suggesting alternative diagnostic methods that might be used in subjects with EA) were excluded. The remaining 153 publications, consisting in case reports and series of cases, were analyzed according to gender, age, allergy history, clinical, laboratory, endoscopic and radiologic features, management and outcome. Over the last years, an uprising interest regarding eosinophilic ascites was registered, with 13 new reports published in the current year. We analyzed 153 publications consisting of case reports and series of cases involving patients with eosinophilic ascites, 17 of them followed by a brief narrative review. Among the analyzed papers 2 of them included animal subjects with gastrointestinal eosinophilic sclerosing fibroplasia[2] and Leiomyosarcoma with paraneoplastic eosinophilia[3]. Among the 171 human subjects described, the age range was from 2 to 76 years at the moment of diagnosis. Of the total subjects, 52% were females, with a most evident difference in patients between 21 and 40 years, while in those under 20 and over 61, an equal gender ratio is noticed.

**Eosinophilic gastroenteritis (EGE)**

In 127 subjects (74%) eosinophilic ascites represented a manifestation of eosinophilic infiltration in the gastrointestinal tract, also known as eosinophilic gastroenteritis (EGE) or eosinophilic enteritis. Eosinophilic tissue infiltration may involve any structure of the digestive tract with symptoms varying according to the affected layer. The gender ratio of 62 males to 65 females (49 to 51%), suggested that females and males have equal chance to develop EA due to EGE.

In 28 cases (22%) history of allergic diseases was reported. With an equal gender ratio, 5 of them[4-8] had nonspecific symptoms, 9 were diagnosed with asthma[9-17], 1 with skin rash[18], while in rest of the patients associations between asthma, allergic rhinitis[19-21], skin rash as well as food, pet and drug allergy were mentioned. Unlike nonallergic patients, almost all patients with signs of allergy had elevated blood eosinophil count (93%) and IgE levels above range. In the absence of allergy, increased IgE levels and eosinophilia were reported mainly in male patients. Almost two thirds 106 (83%) had gastrointestinal symptoms, while the remaining subjects were admitted to the hospital due to increasing abdominal volume (16/21) or constipation.
The most common symptom was abdominal pain in 84 patients, associated with nausea and vomiting (34/84), diarrhea (33/84) and less often with weight loss (8/84).

In addition to the symptoms described above, 29 subjects associated less frequent features like constipation (6/13)[22-26], bloating (1/27), skin rash (4/27-30), fever (3/31-33), edema (2/34-35), malabsorption (1/36), melena (1/37), even signs of pyloric stenosis (3/38-40), intestinal occlusion or subocclusion(6)[41-46], peritonitis secondary to appendicitis (1)[47] and DVT in one patient with acute pancreatitis[48].

Of the cases with documented peritoneal fluid volume(58/127), most (37/58) presented moderate ascites followed by massive (18/58) and mild (3/58) ascites. Several patients, mostly females, associated pleural effusion (17/127), 5 of them bilaterally, and 1 unilateral but massive.

While none of the patients with mild ascites developed pleural effusion, a total of 11 subjects, 7 with moderate ascites and 4 with massive ascites had pleural effusion, probably due to ascitic fluid transfer via transdiaphragmatic lymphatics or diaphragmatic defects. Absolute eosinophil count range in the ascitic fluid was 860 to 13800 per mm3.

The endoscopic evaluation revealed changes in the gastrointestinal mucosa consisting in edema, hyperemia, erosions, ulcerated lesions, mucosal rings, lumen stenosis, nodularity or polyps in 27% (35/127) of the patients. In most of them, endoscopic findings were present in multiple segments of the gastrointestinal tract, while 15 patients had single segment involvement, commonly the stomach or duodenum.

Abdominal ultrasonography and/or CT scan revealed besides different grades of ascites, gastrointestinal wall thickening in 49% (62/127) of the patients, occasionally associated with peritoneal infiltration, peritoneal nodules, abdominal lymphadenopathy (1/34)[49] or splenomegaly (1/34). A quarter of the subjects had only small bowel wall thickening.

Multiple endoscopic biopsies from both normal and abnormal gastrointestinal mucosa showed eosinophil-rich infiltrate in both specimens in more than half of the patients with EA and EGE (74/127). Half of the positive biopsies were obtained from a single gastrointestinal segment. 37% of the patients with GI wall thickening had a single segment involvement, generally small bowel (14/74), stomach (12/74) or colon (8/74).

In 19 cases, although multiple biopsies were performed, their results revealed normal mucosa. Because of negative biopsy results in the absence of pathological features at abdominal echo, CT scans or endoscopy, in 6 subjects[17-18][50-53] laparoscopy with peritoneal biopsies provided valuable information to achieve a definite diagnosis. In 3 patients surgery was not performed, and the diagnosis was established according to clinical and biological criteria[33][54-55].

Two patients with CT scans describing peritoneal involvement[18][56] and another one with gastrointestinal wall thickening[37], underwent surgery and peritoneal fragments from all 3 subjects were sent for histological analysis. In 10 out of 19 cases with endoscopic lesions (1)[34], peritoneal involvement (1)[15], gastrointestinal wall thickening (3)[49][57-58], endoscopic lesions with gastrointestinal wall thickening (1)[59], as well as in peritoneal involvement and gastrointestinal wall thickening association (1)[43], surgery was not performed and definite diagnosis was established on endoscopic and imaging criteria.

In 22 patients (17%) besides EA-EGE, other diseases were reported. EA developed in subjects with preexisting conditions such as: aplastic anemia (1/22)[60], HIV (1/22)[61], celiac disease
(2/22)[15][62], hepatitis B virus infection (1/22)[41] and in subjects with hepatitis C virus infection (2/22) recently treated with Interferon for 14 or 12 weeks[63-64]. Associations between EGE and autoimmune diseases were described in 3 patients: one with systemic lupus erythematosus[65], one with lupus-scleroderma overlap syndrome and heterozygous b-thalassemia[57], and in another one presenting positive antinuclear antibodies[50].

History of pancreatitis[27], as well as recurrent[66-67], self-limiting[27] and acute pancreatitis[48][68-69], were reported in 7 patients. In some cases peritoneal nodules (1/22)[33], liver involvement (2/22)[31][70], eosinophilic dermatitis (1/22) and fasciitis (1/22)[71-72] were described. EA-EGE also affected women in the post-partum period at 8 and 10 weeks postpartum[28][34][73].

A total of 32 subjects underwent surgery, 26 cases for diagnostic laparoscopy, while in 6 patients emergency surgery was performed: appendicectomy(1/6), enterectomy (2/6), subtotal gastrectomy (3/6) in order to resolve the acute episode[13][40][47][60][67][74]. Most subjects (110/127, 87%) were successfully treated with corticosteroids, (95/110) in monotherapy or associations with other drugs (15/110). Corticotherapy was frequently initiated with 40 mg/day of prednisone, but doses below and above were also reported. In addition to CS, dietary measures were recommended in 5 patients[6][19][24][28][75]. CS along with treatments for allergies: Montelukast (2/7)[66], sodium cromoglycate (1)[27], cetirizine (1)[76] and loratadine (1)[42] were also successfully used. Antibiotherapy - Clarithromycin (1) initially 800 mg/day followed by 600 mg/day associated with low dose of CS[54] or cefotaxine (1)[57]- was also reported. Budesonide was added in patients with modified endoscopic features (2)[32][77].

A total of 17 subjects did not receive prednisone for various reasons, but received instead ketotifen (1/17)[78], cefmetazole (1/17)[30], budesonide (1/17)[79] and surgical treatment (3/17) avoiding the need of future medication. Gastric resection represented the solution in 2 patients admitted to the hospital with pyloric obstruction[13][67], while enterectomy was performed in a patient with ileal obstruction[74], all with satisfying results at least for short time. Two patients received only dietary restrictions[80-81], while eight (8/17) recovered spontaneously without medical treatment, although 2 of them presented several self-limited relapses.

There were 15 (12%) patients with relapses among those with EA and EGE. (Table 1) 12/15 patients experienced a single relapse, more common in the first 3 to 6 months[16][27][37][82], while tapering off corticosteroids. Two patients with frequent recurrences, with rapid spontaneous regression, one associating asthma and the other one increased IL5 levels[17][81], did not receive medical treatment at all. Surgery[27][37], ketotifen[82], azathioprine[16], sodium cromoglycate and montelukast[7][66] as monotherapy or in combination with corticosteroids were successfully used while treating relapses. Six patients required long-term steroid therapy[29][40][53][83-85].

**Parasitic and fungal infections:**

A total of 17 cases of EA, 16 associated with parasitic infection and 1 with fungal infection, were identified. Six types of parasites were associated with EA development: Toxocariasis (6 cases)[86-91], Strongyloides stercoralis (5 cases)[92-96], Giardia (1 case)[97], Trichuris.
trichiura (1 case)[98], Ascaris (1 case)[99], Enterobius vermicularis (1 case)[100]. In one patient parasitic etiology[101] was assumed based on therapeutic response to Albendazole administration. Only one case of fungal infection with Coccidioides immitis was reported[102].

With no significant gender difference and age range below 40 years, 64% (12/17) of patients presented hypereosinophilia and 3 of them associated increased IgE levels.

Clinical manifestations included abdominal pain (9/17) and diarrhea (9/17) in most of the subjects, followed by vomiting (4/17), weight loss (3/17) and dysphagia (1/17) as well as signs of cardiac involvement with endomyocardial fibrosis in a patient with Strongyloidiasis. Moderate ascites was present in most of the patients (15/17) and associated with pleural effusion in one.

Endoscopy revealed signs of gastritis and duodenitis in 4 patients, 2 with toxocariasis [88][90], 1 with strongyloidiasis[93] and 1 with trichiuri[98].

Gastrointestinal wall thickening was observed in 6 cases, involving stomach and small bowel in 1 case of trichiuri[98], small bowel and colon in 1 case of enterobiasis[100], stomach in 1 case of ascariasis[99], while patients with coccidioidomycosis[102], strongyloidiasis[93] and toxocariasis[88] had only duodenal wall thickening.

Microscopic eosinophilic infiltration of the GI tract was present in subjects with toxocariasis (3)[86][88][90], strongyloidiasis (1)[93], enterobiasis (1)[100], and in 1 patient with trichiuri in which biopsy specimen of the stomach included a female Trichuris trichiura covered by inflammatory cells[98].

Initially 4 cases were misdiagnosed as EGE due to eosinophilic infiltration in the GI tract and treated with CS, but in the end, all patients received specific treatment with Albendazole, Ivermectin, Pyrantel pamoate or Fluconazole, with a good outcome.

**Hypereosinophilic syndrome (HES)**

Hypereosinophilic syndrome, a myeloproliferative disorder, was diagnosed in 11 patients with ages between 11 and 48, mostly females (54%).

Although all patients had increased eosinophil blood count, history of asthma (2/11) and elevated IgE levels (2/11) were reported only in several patients.

Half of the patients (6/11) had abdominal pain, 2 nausea and vomiting[103-104], 3 diarrhea [103][105-106], 1 weight loss, while others associated signs of cardiac[107] and nervous system[108] involvement.

Abdominal ultrasonography revealed moderate ascites in most cases except for 2 patients who developed mild[103] and large[108] peritoneal effusion. Only one subject with HES associated pleural effusion[108].

Although endoscopic evaluation showed gastroduodenitis[109] and ileal hyperemia[103] in 2 patients, and CT scan revealed small bowel wall thickening[103-104] in other 2 cases, random endoscopic biopsies showed eosinophilic GI infiltration in 5 cases; colon involvement was noticed in 2 cases[104][110], stomach in 1[108], small bowel in 1 case[109] and both esophagus and colon in another one[103].
Of the 11 patients with HES, 7 had single organ involvement: (4/11) gastrointestinal[103][105][110-111], (1/11) pulmonary[112], (1/11) cardiac[107] or (1/11) pancreatic[106] and the diagnosis was confirmed by bone marrow biopsy. In another 3 cases, GI involvement was associated with: cardiac and later on gallbladder involvement[104], eosinophilic cholecystitis due to a common bile duct stricture[109] but also with pulmonary, pleuro-pericardial and central nervous system involvement[108]. Besides a case of Budd-Chiari syndrome associated with HES, subcutaneous nodules and positive FIP1L1-PDGFRA gene were reported[113]. (Table 2)

Most of the patients were treated with prednisone, while some of them received ketotifen (1), budesonide (1) or CS associated with hydroxyurea (1). Two cases of relapse were reported[104-105].

Less common diseases:

A total of 16 cases of EA without EGE, HES or parasitic infection were reported. Two publications described EA associated with pancreatic cancer[114] and secondary to taxol-induced hypersensitivity in a patient treated for ovarian cancer[115] but there was not enough data to analyze the cases. Pathologies associated with EA in the remaining 14 patients, mostly females, with ages between 9 and 76 years are listed in the table below. (Table 3)

GI symptoms such as abdominal pain (6/14), nausea, vomiting (2/14) and diarrhea (1/14) were present in 6 patients. All patients presented with normal IgE level, despite the personal history of asthma (1/14) or rhinitis (1/14).

Hypereosinophilia was present in subjects with eosinophilic pancreatitis[116], eosinophilic peritonitis[117], chronic eosinophilic leukemia[118-119], Churg Strauss Syndrome[120], Systemic lupus erythematosus[121] and Ménétrier's disease[122]. Four patients developed bilateral pleural effusion, one of them with pleural mesothelioma[123].

Abdominal CT revealed peritoneal thickness in a patient with T-cell lymphoma[124], unilateral diaphragm thickening in a patient with pleuro-peritoneal mesothelioma, abdominal lymphadenopathy with mild hepatosplenomegaly in a patient with SLE and small bowel wall thickening in a child with pathological endoscopic findings and microscopic signs of eosinophilic gastric infiltration diagnosed with Ménétrier's disease.

The mechanism responsible for EA development in patients with catamenial pneumothorax[125], granulocytic sarcoma[126], Familial paroxysmal polyserositis[127] and spontaneous bacterial peritonitis with E. Coli[128], remains unclear.

Skin, bone marrow, liver, peritoneal, pleural, and gastric biopsies as well as autoimmune markers and peritoneal fluid analysis along with autopsy[129] in one case were performed to obtain a definite diagnosis.

Additional findings not included in the analysis:

Although excluded from our analysis, EA was reported in 23 papers consisting in studies, 13 of them, including human subjects with EGE[130-142] and 10 of them both animal and human subjects with parasitic infection[143-152].
In nine retrospective studies on 6 to 71 patients with EGE, EA prevalence was between 4 and 88%. When endoscopic biopsies failed to provide a diagnosis, peritoneal fluid analysis, showing high eosinophil count, on its own (9/235) or combined with radiologic imaging (4/235) was considered in order to confirm EGE. One retrospective study involving 10 Asian pediatric patients (mean age 10.8) with EGE and ascites, revealed that in all cases, subjects developed EA as a mark of EGE subserosal layer involvement[134]. With an equal gender ratio, and high eosinophil blood count and endoscopic biopsies revealing eosinophilic infiltrate in all of the patients, 60% had history of allergy, 100% abdominal pain, followed by vomiting (30%) and diarrhea (20%). CS were successfully used in all subjects.

Regarding studies involving human subjects with parasitic infections, EA developed mostly in patients with anisakiasis (63%; 78%)[149-150], followed by those with strongyloidiasis (60%)[148], paragonimiasis (32%)[143] and less frequent in those with ancylostomiasis (9%)[151].

In addition aspects regarding novel approach in the diagnosis of patients with EA of unknown origin or EA associated with EGE, such as Natural orifice transluminal endoscopic surgery (NOTES), ultrasound-guided percutaneous fine-needle biopsy, are also proposed[45][153-154].

**DISCUSSION**

Eosinophilic ascites has been reported mostly in patients with EGE, HES and parasitic infections. (Fig 2)

Eosinophilic gastroenteritis (EGE) is an inflammatory gastrointestinal disease affecting both children and adults, mainly males. Eosinophilic infiltration is present in one or more areas of the GI tract, without other organ involvement and in the absence of an identified cause of eosinophilia.

Hypereosinophilic syndrome (HES) is a myeloproliferative disorder characterized by persistent eosinophilia, associated with damage to multiple organs. (Table 4)

Whether associated with EGE, HES, parasitic infection or less common diseases females (52%) and males have almost equal chance to develop EA.

The elevated eosinophil blood count is found mainly in EA patients with HES (90%), EGE (74%) and parasitic infection (69%). Besides, subjects with increased eosinophilia may be diagnosed with less frequent pathologies such as eosinophilic pancreatitis, eosinophilic peritonitis, chronic eosinophilic leukemia, Churg Strauss Syndrome and Ménétrier's disease. Some studies reported eosinophilia during chronic pancreatitis, without evidence of eosinophilic pancreatic tissue infiltrate.[155-156]

While referring to IgE levels, there was no significant difference between EA patients with EGE (19%), HES (18%) and parasitosis (19%).

Patients with EA describe often nonspecific gastrointestinal symptoms such as abdominal pain, nausea/vomiting, diarrhea and occasionally weight loss.

In patients with EA and EGE, clinical features vary according to the involved gastrointestinal layer and site.[157] (Table 5)
We compared the prevalence of digestive symptoms (abdominal pain, nausea, and vomiting, diarrhea) in patients with EGE, HES, parasitic infections and in those with less common pathologies.

Patients with EA and EGE (83%), HES (81%) and parasitosis (70%) described at least one gastrointestinal symptom. Abdominal pain and nausea or vomiting appear to be more common in patients with EGE (66%; 31%), while diarrhea is reported mostly in patients with parasitic infections (53%). Weight loss was also reported in some patients, frequently in those with parasitic infections.

Abdominal ultrasound, endoscopic examination and sometimes CT scan are current investigations performed in patients presenting with gastrointestinal symptoms. Beside routine blood tests and peritoneal fluid analysis, stool analysis for ova and parasites along with serology should be performed to exclude parasitic infection.

Studies performed on animal subjects revealed that parasitic infection caused marked absolute eosinophilia, and focal eosinophil infiltrate in the gastrointestinal layers, mimicking eosinophilic gastroenteritis[145][148][150-151][158]. In humans, Toxocara, Strongyloides stercoralis, Giardia, Trichuris trichiura, Ascaris and Enterobius vermicularis are responsible for most parasitic infections, while infections due to Setaria species and Cestoda were reported only in animals. Upper and lower endoscopy often revealed nonspecific lesions such as edema, hyperemia, erosions, ulcerated lesions, mucosal rings, lumen stenosis, nodularity or polyps, mostly in EA patients with EGE.

Regarding patients with EA-EGE, biopsies from abnormal mucosa showed in most cases eosinophilic mucosal infiltration (77%, 27/35). 80% (28/35) of the patients with endoscopic lesions associated imaging findings of gastrointestinal wall thickening. Of the total 62 patients with gastrointestinal wall thickening observed in at least one GI segment, in 72% microscopic eosinophilic mucosal infiltration was confirmed.

Although EGE diagnosis is confirmed by histological examination, radiological features suggesting an inflammatory process, combined with typical clinical manifestations, may lead to the correct diagnosis[159]. CT findings are also helpful for assessing the extent and location of the disease, while abdominal ultrasound can represent a suitable follow-up method.

In patients with high suspicion of gastroenteritis involving muscular and subserosal layers as well as small bowel segments, other investigations such as Ultrasound-guided percutaneous fine-needle biopsy[45] or capsule endoscopy and double-balloon enteroscopy[160] may be performed as an alternative to laparoscopy to achieve a definite diagnosis.

Dosing IL5 and IL2 receptor levels, in the blood and peritoneal fluid, might have predictive value for relapses, while ascitic fluid level of complements C3 or C4[154] might help rule out liver disease origin in EA patients.

EA-EGE was also described in patients with autoimmune diseases: scleroderma, SLE, polymyositis, dermatomyositis[57][65] and celiac disease [15][62]. EA in postpartum females, mainly associated with EGE, was also reported in three cases[28][34][73]. Pancreatitis associated with EGE is believed to be due to eosinophilic infiltration leading to edema, fibrosis and distortion in the ampulla and periampullary duodenum[66].
Some authors suggest that diffuse eosinophilic gastroenteritis, along with EA, could be isolated manifestations of the hypereosinophilic syndrome[107][112][161]. In EA patients with elevated eosinophil blood count, screening for other organ involvement and hematological evaluation, including PDGFRA-FIP1L1 gene mutation, bone marrow aspirate and biopsy, should be performed to rule out HES. Although less frequent, peritoneal tuberculosis should also be ruled out[162].

While patients with parasitosis and hematological disorders such as T cell lymphoma and chronic eosinophilic leukemia require specific treatment, in patients with food allergy dietary treatment should be the first therapeutic measure, especially in children. Corticosteroids are currently the best line of EA treatment in both patients with EGE and HES. Enteric coated budesonide[32][79][163] and mast cell stabilizer medications such as Ketotifen[78], represented alternatives to prednisone treatment in EA patients with EGE and HES, while leukotriene receptor antagonists (Montelukast, Sodium Cromoglycate)[7][27][66], histamine antagonist (Loratadine, Cetirizine)[42][76] and immunosuppressive medication (Azathioprine)[16] were used in relapse treatment. (Fig. 3)

CONCLUSION

In most cases, in the absence of allergy, parasitic infections, malignancy, hematological disorders, peritoneal tuberculosis, inflammatory bowel disease, autoimmune disease, Eosinophilic ascites develops as a manifestation of EGE. Although laparoscopic serosal biopsies are required for a definite diagnosis, ascitic fluid eosinophilia, radiological findings such as gastrointestinal wall thickening, peritoneum infiltration and response to steroid treatment indirectly confirm the diagnosis of EGE. Therapy with corticosteroids results in resolution of eosinophilic ascites in almost all patients at least for short time.

Introducere: În ultimii ani se constată un interes în creștere fața de o patologie relativ nestudiată, ascita eozinofilică. Scopul lucrării este să investigheze cauzele care duc la apariția acestei patologii, analizând caracteristici clinice, biologice, endoscopice, imagistice, precum și tratamentul și evoluția ulterioară a pacienților cu ascită eozinofilică.

Materiale și metode: Au fost introduse în motorul de căutare al bazei de date PubMed termenii “Ascites” AND “Eosinophils”.

Rezultate: Din cele 284 de articole publicate din 1962 până în prezent, 131 au fost excluse pentru că nu au îndeplinit criteriile de includere. Din totalul de 171 de pacienți cu ascită eozinofilică, colectați din cele 153 cazuri și serii de cazuri publicate, 127 (74%) au fost diagnosticați cu gastroenterită eozinofilică, 17 (10%) cu infecții parazitare sau fungice, 11 (7%) cu Sindrom hiperezinofilic, iar 16 (9%) cu patologii mai puțin frecvente (pancreatăță eozinofilică, leucemie cronifică eozinofilică, mielofibroză, limfom cu celulară T, Sindrom Churg Strauss, lupus eritematos sistematic, febră mediteraneană familială și boală Ménétrier). Hiperezinofilia, valorile crescute ale IgE și manifestările digestive sunt caracteristici frecvent întâlnite la pacienții cu ascită eozinofilică. Diagnosticul se stabilește în urma analizei lichidului de ascită, a modificarilor radiologice și endoscopice, iar tratamentul constă în coticoterapie, cu evoluție favorabilă în majoritatea cazurilor.
Concluzii: De cele mai multe ori, în lipsa alergiei, infecțiilor parazitare, neoplaziei, tuberculozei intestinale, bolilor inflamatorii intestinale și patologiilor hematologice sau autoimune, ascita eozinofilică este o manifestare în cadrul gastroenteritei eozinofilice.

Correspondence to: Larisa Pinte, M.D., Internal Medicine Department, Colentina Clinical Hospital, 19-21 Stefan cel Mare Boulevard, sect 2, 020125 Bucharest, Romania
Email: larissa.0806@yahoo.com

Declaration of interest: The authors state there is no conflict of interest.

Abbreviations: EA: eosinophilic ascites; EGE: eosinophilic gastroenteritis; GI: gastrointestinal; HES: Hypereosinophilic syndrome; SLE: Systemic lupus erythematosus; SAAG: serum-ascites albumin gradient; IgE: immunoglobulin E; IL: interleukin; CS: corticosteroids

References:

60. TSUJIO G., AOMATSU N., WANG E., YAMAKOSHI Y., NAGASHIMA D., HIRAKAWA T et al., “[A Case of Eosinophilic Enteritis Needed to Distinguish from a Tumor of the Small Intestine],” Gan To Kagaku Ryoho., vol. 43, no. 12, 2016, pp. 1863–1865.
63. HIRANO G., FUKUNAGA A., SOHDA T., KUNIMOTO H., YOTSUMOTO K,


116. RAKESH K., BANERJEE R, GUPTA R, RAMJI C, PRADEEP R, RAO GV et al.,


140. JEON E. J., LEE KM., JUNG DY., KIM TH., JI JS., KIM HK et al., “[Clinical characteristics of 17 cases of eosinophilic gastroenteritis].”, Korean J. Gastroenterol., 2010, vol. 55, no. 6, pp. 361–7.


Received 12th December 2018
<table>
<thead>
<tr>
<th>Ref</th>
<th>Initial treatment</th>
<th>Number of relapses</th>
<th>Period until relapse</th>
<th>Solution</th>
</tr>
</thead>
<tbody>
<tr>
<td>[37]</td>
<td>CS</td>
<td>1</td>
<td>3 months (intestinal pseudo-obstruction)</td>
<td>surgery</td>
</tr>
<tr>
<td>[82]</td>
<td>CS</td>
<td>1</td>
<td>4 months</td>
<td>Ketotifen</td>
</tr>
<tr>
<td>[16]</td>
<td>CS</td>
<td>1</td>
<td>4 months</td>
<td>Azathioprine</td>
</tr>
<tr>
<td>[27]</td>
<td>Sodium cromoglycate</td>
<td>1</td>
<td>6 months</td>
<td>surgery, CS and Sodium cromoglycate</td>
</tr>
<tr>
<td>[66]</td>
<td>CS and Montelukast</td>
<td>1</td>
<td>1 year</td>
<td>CS and Montelukast again</td>
</tr>
<tr>
<td>[17]</td>
<td>-</td>
<td>2</td>
<td>2 episodes during a 4 year period</td>
<td>Resolved spontaneously each time</td>
</tr>
<tr>
<td>[83]</td>
<td>CS</td>
<td>1</td>
<td>4 years (repeated Ab administration)</td>
<td>CS</td>
</tr>
<tr>
<td>[81]</td>
<td>-</td>
<td>4</td>
<td>4 episodes during a 4 year period</td>
<td>Resolved each time spontaneously</td>
</tr>
<tr>
<td>[40]</td>
<td>Gastrectomy</td>
<td>1</td>
<td>5 years</td>
<td>CS</td>
</tr>
<tr>
<td>[53]</td>
<td>CS</td>
<td>1</td>
<td>When stopping CS</td>
<td>CS (5 mg) on alternate days</td>
</tr>
<tr>
<td>[7]</td>
<td>CS</td>
<td>1</td>
<td>While tapering off CS</td>
<td>Montelukast added</td>
</tr>
<tr>
<td>[54]</td>
<td>CS</td>
<td>2</td>
<td>While tapering off CS</td>
<td>CS and clarithromycin first 800 mg/day, than 600 mg/day</td>
</tr>
<tr>
<td>[84]</td>
<td>CS</td>
<td>1</td>
<td>Nd</td>
<td>Intermittent courses of CS</td>
</tr>
<tr>
<td>[85]</td>
<td>CS</td>
<td>1</td>
<td>Nd</td>
<td>CS dependency</td>
</tr>
<tr>
<td>[29]</td>
<td>CS</td>
<td>1</td>
<td>Nd</td>
<td>CS (8mg)</td>
</tr>
</tbody>
</table>

CS = corticosteroids, nd = no data
Table 2. Organ involvement in patients with HES

<table>
<thead>
<tr>
<th>Ref</th>
<th>Condition</th>
</tr>
</thead>
<tbody>
<tr>
<td>[103][105][110][111]</td>
<td>GI involvement (4/11)</td>
</tr>
<tr>
<td>[112]</td>
<td>Pulmonary involvement (1/11)</td>
</tr>
<tr>
<td>[106]</td>
<td>Pancreatic involvement (1/11)</td>
</tr>
<tr>
<td>[107]</td>
<td>Cardiac involvement (1/11)</td>
</tr>
<tr>
<td>[104]</td>
<td>GI, cardiac and later on colecystic involvement (1/11)</td>
</tr>
<tr>
<td>[109]</td>
<td>GI (s+sb) and eosinophilic cholecystitis with common bile duct stricture (1/11)</td>
</tr>
<tr>
<td>[113]</td>
<td>Budd-Chiari syndrome associated with HES, subcutaneous nodules FIP1L1 and PDGFRA gene mutations (1/11)</td>
</tr>
<tr>
<td>[108]</td>
<td>HES with stomach wall involvement, interstitial lung disease, pleural and pericardial effusion. central nervous system involvement (Grand mal epilepsy) (1/11)</td>
</tr>
</tbody>
</table>

s+sb = stomach and small bowel
<table>
<thead>
<tr>
<th>Ref</th>
<th>gender</th>
<th>GI symptoms</th>
<th>Other findings</th>
<th>Diagnosis</th>
<th>Means of diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 [125]</td>
<td>F</td>
<td>no</td>
<td>Weight loss</td>
<td>catamenial pneumothorax</td>
<td></td>
</tr>
<tr>
<td>2 [120]</td>
<td>M</td>
<td>no</td>
<td>dyspnoea, purpura, edema, symmetrical sensory peripheral neuropathy</td>
<td>Churg Strauss Syndrome</td>
<td>skin biopsy</td>
</tr>
<tr>
<td>3 [117]</td>
<td>F</td>
<td>Abdominal pain, nausea, vomiting, diarrhea</td>
<td>no</td>
<td>eosinophilic peritonitis</td>
<td>Ascites</td>
</tr>
<tr>
<td>4 [118]</td>
<td>M</td>
<td>no</td>
<td>spinal cord compression, trisomy 8</td>
<td>chronic eosinophilic leukemia(extradural eosinophilic chloroma)</td>
<td>Bone marrow biopsy</td>
</tr>
<tr>
<td>5 [119]</td>
<td>F</td>
<td>no</td>
<td>hepatomegaly</td>
<td>chronic eosinophilic leukemia</td>
<td>Liver biopsy</td>
</tr>
<tr>
<td>6 [116]</td>
<td>F</td>
<td>Abdominal pain</td>
<td>pancreatic pseudocyst</td>
<td>eosinophilic pancreatitis</td>
<td>nd</td>
</tr>
<tr>
<td>7 [124]</td>
<td>M</td>
<td>Abdominal pain</td>
<td>no</td>
<td>T-cell lymphoma</td>
<td>Peritoneal FNA CT guided</td>
</tr>
<tr>
<td>8 [126]</td>
<td>F</td>
<td>Abdominal pain</td>
<td>jaundice</td>
<td>granulocytic sarcoma</td>
<td>Ascites</td>
</tr>
<tr>
<td>9 [128]</td>
<td>M</td>
<td>Abdominal pain</td>
<td>no</td>
<td>spontaneous bacterial peritonitis (E Coli)</td>
<td>Ascites</td>
</tr>
<tr>
<td>10 [123]</td>
<td>M</td>
<td>no</td>
<td>back pain</td>
<td>pleural and peritoneal mesothelioma</td>
<td>parietal pleura (thoracoscopy)</td>
</tr>
<tr>
<td>11 [121]</td>
<td>F</td>
<td>no</td>
<td>fever, skin lesion, thrombocytopenia, anemia</td>
<td>Systemic lupus erythematosus</td>
<td>Coombs, ANA +, DNAde</td>
</tr>
<tr>
<td>12 [127]</td>
<td>F</td>
<td>no</td>
<td>no</td>
<td>Familial paroxysmal polyserositis</td>
<td>response to colchicine</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Abdominal pain, nausea, vomiting</strong></td>
<td>edema</td>
<td>Ménétrier's disease</td>
<td>Gastric biopsy</td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>--------------------------------------</td>
<td>-------</td>
<td>---------------------</td>
<td>---------------</td>
</tr>
<tr>
<td>13 [122]</td>
<td>F</td>
<td>Abdominal pain, nausea, vomiting</td>
<td>edema</td>
<td>Ménétrier's disease</td>
<td>Gastric biopsy</td>
</tr>
<tr>
<td>14 [129]</td>
<td>nd</td>
<td>no</td>
<td>no</td>
<td>myelofibrosis</td>
<td>autopsy</td>
</tr>
</tbody>
</table>

nd- no data
Table 4. Hypereosinophilic Syndrome diagnostic criteria (Chusid, 1975)

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Sustained blood eosinophilia greater than 1500/mm³ for longer than 6 months</td>
</tr>
<tr>
<td>2</td>
<td>No identifiable etiology for eosinophilia</td>
</tr>
<tr>
<td>3</td>
<td>Signs and symptoms of organ involvement</td>
</tr>
<tr>
<td>Layer involved</td>
<td>Clinical features</td>
</tr>
<tr>
<td>----------------</td>
<td>----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>mucosal</td>
<td>abdominal pain, nausea, vomiting, diarrhea, blood loss in the stool, iron deficiency anemia, malabsorption, protein-losing enteropathy</td>
</tr>
<tr>
<td>muscle</td>
<td>bowel wall thickening with obstructive gastrointestinal symptoms</td>
</tr>
<tr>
<td>subserosal</td>
<td>bloating, exudative ascites, higher peripheral eosinophil counts</td>
</tr>
</tbody>
</table>
Fig 1. Papers with evidence of EA from 1962 onwards
Fig 2. Causes of EA development

284 publications
131 excluded
- 76 without evidence of EA
- 29 narrative reviews
- 26 studies (EA was not the inclusion criteria)

153 publications (case reports, series of cases)
= 171 EA cases

EGE 127 cases (74%)
Parasitic & fungal infections 17 cases (10%)
HES 11 cases (7%)
Less common diseases 16 cases (9%)
Fig 3. EA diagnostic and treatment algorithm (based on our findings and British Society for Hematology Guidelines, *Guideline for the investigation and management of eosinophilia*)

**Hypereosinophilia**
- **Allergy?**
  - yes → Treatment
  - no → Diarrhea, Protein losing enteropathy

**ASCITES**
- (high eosinophil count)
  - positive → Treatment
  - negative → parasitic infection?
    - positive → Rule out: Malignancy, Peritoneal tuberculosis, IBD, Vasculitis (Churg-Strauss Syndrome), Autoimmune disease
    - negative → Endoscopy with biopsy

**Tissue eosinophilia**
- (≥ 20/HPF)
  - negative → Consider:
    - Enteroscopy
    - EUS-fine needle biopsy
    - NOTES
    - Surgery with full thickness biopsy
  - positive → EGE (subserosal type)

**Hypereosinophilic syndrome**
- diagnostic work-up
- Asymptomatic patients:
  - serum troponin every 3-6 months
  - echocardiography/pulmonary function tests every 6-12 months
- Symptomatic patients:
  - without FIP1L1-PDGFRα:
    1. Steroids (prednisone 1 mg/kg/d or 60 mg/d)
    2. Hydroxyurea/Interferon α
    3. Imatinib (400 mg/d)
  - with FIP1L1-PDGFRα:
    1. Imatinib
    2. Chemotherapeutic agents
    3. Hematopoietic stem cell transplantation

**Dietary treatment for 4-6 weeks**
- (reduction of 50% in the peripheral eosinophil count)
  - Steroids
  - Steroid sparing drugs:
    - Mast cell stabilizers
    - Leukotriene receptor antagonists (Montelukast)
    - Macrolides (Clarithromycin)